Copyright
©The Author(s) 2020.
World J Clin Oncol. Nov 24, 2020; 11(11): 854-867
Published online Nov 24, 2020. doi: 10.5306/wjco.v11.i11.854
Published online Nov 24, 2020. doi: 10.5306/wjco.v11.i11.854
Figure 1 Side effects are distinct from the anticancer mechanism.
An exemplary case concerning taxol is depicted. TSLP: Tumor-specific lytic path; >: Greater than microbutule-disruping dose; =: Equivalent to microtubule-disrupting dose; <: Lesser than microtubule-disrupting dose; NSP: Nonspecific.
- Citation: Hong F, Castro M, Linse K. Tumor-specific lytic path “hyperploid progression mediated death”: Resolving side effects through targeting retinoblastoma or p53 mutant. World J Clin Oncol 2020; 11(11): 854-867
- URL: https://www.wjgnet.com/2218-4333/full/v11/i11/854.htm
- DOI: https://dx.doi.org/10.5306/wjco.v11.i11.854